Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia

This study highlights HZX-02-059, a dual-target inhibitor of #PIKfyve & #Tubulin, as lethal to #Bcell #AcuteLymphoblasticLeukaemia cells, underscoring its potential as a #therapeutic candidate for targeted #CancerTherapy. #medsky
Read: link.springer.com/article/10.1...

The dual inhibitors of the lipid kinases, #PIKfyve & #PIP4K2C, have a mechanism of action that plays a role in inhibiting #SARSCoV2 entry
- High genetic barrier to resistance: Targeting host cellular functions rather than viral proteins